Is JEVTANA a taxane?

JEVTANA has a taxane chemical structure. It is the only microtubule inhibitor approved in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with a docetaxel-containing regimen.1

Learn about the mechanism of action for JEVTANA.

How has JEVTANA been studied?

The efficacy and safety of JEVTANA were evaluated in more than 2200 metastatic castration-resistant prostate cancer (mCRPC) patients who received a docetaxel-containing regimen. The pivotal TROPIC trial validated JEVTANA as a treatment in mCRPC after docetaxel and the PROSELICA trial established JEVTANA 20 mg/m2 as the recommended dose. In the CARD trial, JEVTANA was studied as a 3rd-line therapy post-docetaxel and after either abiraterone or enzalutamide.1

Learn more about how JEVTANA was studied and see the results.

How is JEVTANA administered?

JEVTANA is an infusion medicine administered by a trained professional.1

Find out more about how JEVTANA is administered.

What is the recommended dose of JEVTANA?

The recommended dose of JEVTANA is based on calculation of the body surface area (BSA) and is 20 mg/m2 in combination with oral prednisone 10 mg administered daily throughout JEVTANA treatment. A dose of 25 mg/m2 can be used in select patients at the discretion of the treating healthcare provider.1

See more information about the recommended dose of JEVTANA.

When can JEVTANA be prescribed?

JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen.1

Learn more about how JEVTANA has been studied in men with mCRPC.

Where can I find helpful resources for my practice?

There are helpful resources, including billing and coding information that provides details needed for submitting a reimbursement claim and a clinician’s guide that gives a detailed overview of treatment with JEVTANA.

Download these helpful resources.

Is there financial assistance available for patients being treated with JEVTANA?

CareASSIST by Sanofi Genzyme for JEVTANA offers resources and support for your eligible patients, including access and reimbursement within the insurance landscape, financial assistance that can help mitigate the cost of JEVTANA, and resource support for both patients and caregivers.

To see the full scope of CareASSIST offerings and to find out if your patients are eligible, visit the CareASSIST website.